KSCM
AMAG

Kamunting Street Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Kamunting Street Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-67,460
Closed -$894K – 36
2017
Q4 		$894K Buy
67,460
+55,160
+448% +$832K 0.64% 26
2017
Q3 		$227K Buy
+12,300
New +$229K 0.14% 33

Other funds holding AMAG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kamunting Street Capital Management's AMAG Position: Q1 2018 in Review

Kamunting Street Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q1 2018, closing a stake of 67,460 shares — an estimated $894K sold.

Kamunting Street Capital Management first reported a position in AMAG in Q3 2017 and held it in 2 quarters. The position peaked at $894K in Q4 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q1 2018.

  • Kamunting Street Capital Management reported no remaining AMAG Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Kamunting Street Capital Management sold 67,460 AMAG Pharmaceuticals shares in Q1 2018, an estimated $894K.
  • Kamunting Street Capital Management first reported a position in AMAG Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Kamunting Street Capital Management's AMAG Pharmaceuticals position peaked at $894K in Q4 2017.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2018.

Based on Kamunting Street Capital Management's 13F filing for Q1 2018, filed 15 May 2018.